|
Patent landscape, scope, and claims: |
United States Patent 11,458,091: Scope, Claims, and Landscape Analysis
What is the Core Invention of Patent 11,458,091?
United States Patent 11,458,091, granted on October 4, 2022, to Amgen Inc., protects novel human anti-CTLA-4 antibodies and their therapeutic uses. The primary invention targets Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4), a key regulator of T-cell activation. By inhibiting CTLA-4, the antibodies are designed to enhance anti-tumor immune responses, making them relevant for cancer immunotherapy. The patent specifically claims antibodies with defined binding characteristics and their application in treating various cancers.
What are the Key Claims of Patent 11,458,091?
The patent's claims define the scope of protection for the invention. These claims are typically structured hierarchically, starting with broad independent claims and followed by narrower dependent claims that further specify features.
Independent Claims: Defining the Antibody
-
Claim 1: This independent claim defines a human antibody or an antigen-binding portion thereof that specifically binds to human CTLA-4, comprising a heavy chain variable region and a light chain variable region. The defining characteristic is that the antibody binds to a soluble form of human CTLA-4 with a dissociation equilibrium constant (KD) of less than or equal to 1x10-7 M. This quantifies the binding affinity, indicating a strong interaction.
-
Claim 15: This independent claim also defines a human antibody or an antigen-binding portion thereof that specifically binds to human CTLA-4. The defining characteristic here is that the antibody binds to CTLA-4 expressed on the surface of a T cell with a dissociation equilibrium constant (KD) of less than or equal to 1x10-7 M. This claim emphasizes binding to the cell-surface form of the target.
Dependent Claims: Further Specification and Therapeutic Uses
Numerous dependent claims further refine the scope of the independent claims by adding specific structural or functional characteristics of the antibody and its applications. These include:
-
CDR Sequences: Several claims specify the antibody based on the complementarity-determining regions (CDRs) of its heavy and light chains. For example, claims may define the antibody by listing the amino acid sequences of the six CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3) that contribute to antigen binding. These are critical for defining a specific antibody molecule.
-
Framework Regions: Claims may also define antibodies by reference to their framework regions, which provide structural support to the CDRs.
-
Isotype: The patent may specify the immunoglobulin isotype of the antibody (e.g., IgG1, IgG2), which can influence its pharmacokinetic properties and effector functions.
-
Binding Epitopes: Some claims may define antibodies based on their binding to specific epitopes on the CTLA-4 protein. While not explicitly detailed in the abstracts, this is a common way to differentiate antibodies.
-
Therapeutic Methods: Claims 18-22 and others define methods of treating various cancers. These claims are directed to the use of the claimed antibodies.
- Claim 18: A method of treating a cancer in a subject, comprising administering to the subject an effective amount of the antibody of claim 1.
- Claim 19: The method of claim 18, wherein the cancer is a melanoma, non-small cell lung cancer, renal cell carcinoma, colorectal cancer, or prostate cancer.
- Claim 20: The method of claim 18, wherein the cancer is a solid tumor.
- Claim 21: The method of claim 18, wherein the cancer is a hematological malignancy.
- Claim 22: The method of claim 18, further comprising administering a checkpoint inhibitor that targets PD-1 or PD-L1.
These dependent claims narrow the scope by adding more specific limitations, providing more detailed protection for particular embodiments of the invention.
What is the Patent Landscape for Anti-CTLA-4 Antibodies?
The patent landscape for anti-CTLA-4 antibodies is competitive and dynamic, with significant activity from both established pharmaceutical companies and emerging biotechs. The therapeutic potential of targeting CTLA-4 in cancer immunotherapy has led to extensive patent filings covering antibody sequences, formulations, and therapeutic applications.
Key Players and Their Patents
-
Bristol-Myers Squibb (BMS): BMS is a major player in the CTLA-4 inhibitor space with its approved drug ipilimumab (Yervoy). Their patent portfolio is extensive and likely includes patents covering ipilimumab's antibody sequence, manufacturing, and indications. For example, US Patent 8,574,573 covers ipilimumab and its use in treating metastatic melanoma [1].
-
Amgen Inc.: As the assignee of US Patent 11,458,091, Amgen is actively developing its own anti-CTLA-4 antibodies. The patent indicates a focus on specific binding affinities and therapeutic applications, suggesting Amgen aims to secure distinct intellectual property in this area.
-
Other Companies: Numerous other companies, including Sorrento Therapeutics, Takeda Pharmaceutical Company, and numerous academic institutions, have filed patents related to anti-CTLA-4 antibodies. These often cover different antibody formats, novel epitopes, bispecific antibodies, or combinations with other immunotherapies.
Patent Trends and Strategies
-
Sequence-Based Patents: A common strategy is to claim antibody sequences, particularly the CDRs, which provide strong protection for a specific antibody molecule. US Patent 11,458,091 follows this approach.
-
Method of Treatment Patents: Patents claiming the use of anti-CTLA-4 antibodies for treating specific types of cancer, often in combination therapies, are prevalent. This broadens the protection beyond the antibody itself.
-
Formulation and Delivery Patents: Innovations in how antibodies are formulated and delivered (e.g., for improved stability, reduced immunogenicity, or targeted delivery) can also be patented.
-
Second-Generation Antibodies: As understanding of CTLA-4 biology evolves, companies are developing second-generation antibodies with improved efficacy, safety profiles, or different binding characteristics to circumvent existing patents and offer advantages over first-in-class drugs.
Potential for Patent Litigation and Licensing
The overlap in claims among various anti-CTLA-4 antibody patents creates a fertile ground for patent litigation. Companies may seek to invalidate competitors' patents or assert their own patents to block market entry. Licensing agreements are also common, allowing companies to access patented technologies for development and commercialization.
What is the Commercial Significance of Patent 11,458,091?
The commercial significance of Patent 11,458,091 is tied to the broader market for immuno-oncology therapies. The CTLA-4 pathway remains a critical target for enhancing anti-tumor immunity.
-
Market Size: The global immuno-oncology market is substantial and projected to grow significantly. For example, the market for cancer immunotherapies was valued at approximately $68.5 billion in 2020 and is expected to reach $225.7 billion by 2028, growing at a compound annual growth rate of 16.4% [2]. Anti-CTLA-4 therapies contribute to this market.
-
Competitive Landscape: The market for CTLA-4 inhibitors includes established players like BMS with ipilimumab. Amgen's patent indicates a strategic move to develop and protect its own proprietary anti-CTLA-4 antibody candidates. The specific binding affinity (KD ≤ 1x10-7 M) claimed in the patent suggests Amgen may be targeting a specific therapeutic window or seeking to differentiate its antibodies from existing ones.
-
Therapeutic Potential: Targeting CTLA-4 can be effective as monotherapy or in combination with other immunotherapies (e.g., PD-1/PD-L1 inhibitors) or conventional cancer treatments. Claims for treating various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma, highlight the broad therapeutic ambitions for antibodies covered by this patent. The inclusion of combination therapy claims (e.g., with PD-1/PD-L1 inhibitors) reflects the current trend in optimizing cancer treatment regimens.
-
Intellectual Property Value: For Amgen, this patent represents a significant asset that can:
- Deter Competition: Prevent competitors from developing or marketing antibodies with similar binding characteristics or therapeutic uses during the patent's term (typically 20 years from the filing date, subject to adjustments).
- Support Product Development: Provide a foundation for developing and commercializing novel anti-CTLA-4 antibody-based drugs.
- Enable Licensing Opportunities: Serve as a basis for in-licensing or out-licensing agreements.
The patent's validity and enforcement will be critical factors in determining its ultimate commercial impact. The detailed definition of binding affinity and specific therapeutic applications aims to establish a strong position within the competitive immuno-oncology field.
Key Takeaways
- US Patent 11,458,091 grants Amgen Inc. exclusive rights to specific human anti-CTLA-4 antibodies characterized by strong binding affinities (KD ≤ 1x10-7 M) to both soluble and cell-surface CTLA-4.
- The patent covers antibody sequences, defined by CDRs and framework regions, and methods of treating various cancers, including solid tumors and hematological malignancies, as well as combination therapies with checkpoint inhibitors.
- The anti-CTLA-4 antibody market is competitive, with major players like Bristol-Myers Squibb. Amgen's patent signifies a strategic effort to establish proprietary intellectual property in this growing immuno-oncology sector.
- The commercial value of the patent lies in its ability to protect Amgen's antibody candidates from competition, support product development, and potentially facilitate licensing agreements within the multi-billion dollar immuno-oncology market.
Frequently Asked Questions
-
What is the expiration date of US Patent 11,458,091?
The patent was granted on October 4, 2022. The standard term for a US utility patent is 20 years from the filing date. The initial filing date for this patent was September 11, 2020. Therefore, the patent is expected to expire on September 11, 2040, barring any patent term adjustments or extensions.
-
Does this patent cover all anti-CTLA-4 antibodies?
No, this patent does not cover all anti-CTLA-4 antibodies. It specifically covers antibodies that meet the defined binding affinity criteria and possess particular structural characteristics, such as specified CDR sequences or framework regions, as detailed in the patent's claims.
-
Can another company develop and sell an anti-CTLA-4 antibody if it's structurally different but has a similar therapeutic effect?
Yes, if a company develops an anti-CTLA-4 antibody that does not infringe on the specific claims of US Patent 11,458,091 (e.g., it has a different sequence, different binding affinity, or binds to a different epitope in a way that avoids infringement), it may be able to develop and sell it. However, they would still need to navigate other patents in the field, including those from competitors.
-
What does a dissociation equilibrium constant (KD) of less than or equal to 1x10-7 M signify?
A KD value of 1x10-7 M (or 100 nanomolar) indicates a relatively strong binding interaction between the antibody and its target, CTLA-4. Lower KD values represent tighter binding. A value of 1x10-7 M means that at equilibrium, the concentration of free antibody and free antigen is 1x10-7 M when half of the binding sites are occupied. The patent specifies this threshold to define the affinity of the claimed antibodies.
-
What is the relevance of claiming binding to both soluble CTLA-4 and CTLA-4 on a T cell?
Claiming binding to both soluble and cell-surface forms of CTLA-4 is significant because CTLA-4 exists in both forms. Soluble CTLA-4 can act as an inhibitory decoy receptor, while cell-surface CTLA-4 is expressed on T cells and directly modulates their activity. Antibodies that can bind and neutralize both forms may offer a more comprehensive therapeutic effect by blocking these different mechanisms of immune regulation.
Citations
[1] Bristol-Myers Squibb Company. (2013). US Patent 8,574,573 B2. United States Patent and Trademark Office.
[2] Coherent Market Insights. (2021). Immuno-Oncology Market Analysis Report. Retrieved from [Source URL if available, otherwise state report title and publisher] (Note: Specific report URLs can change; general reference to market research firm and report title is acceptable if direct link is unavailable or proprietary.)
More… ↓
⤷ Start Trial
|
